和铂医药（上海）有限公司 Harbour BioMed
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting 2021-04-13 14:55
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China 2021-03-22 10:31
Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial 2021-03-12 09:00
Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors 2021-02-26 10:16
Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis 2021-01-28 12:54
Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange 2020-12-17 08:19
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials 2020-12-15 08:00
HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering 2020-12-09 17:29
Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society 2020-11-16 20:17
Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia 2020-09-30 21:50
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors 2020-09-21 20:12
Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs 2020-09-11 21:33
Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020 2020-09-02 11:40
Harbour BioMed Will Present Its New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit 2020-08-31 21:39
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases 2020-08-24 19:00
Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020 2020-08-21 21:31
Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19 2020-08-19 19:43
Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups 2020-07-31 08:56
Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting 2020-07-16 18:00
Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board 2020-06-11 18:00
1 2 3 4 5